A. Legal Requirement, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA
Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 [Statutory Instrument 2004/1031], as amended by Statutory Instrument 2006/1928, contains a requirement for the notification of “serious breaches” of GCP or the trial protocol:
“29A. (1) The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of –
(a) the conditions and principles of GCP in connection with that trial; or
(b) the protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach.
(2) For the purposes of this regulation, a “serious breach” is a breach which is likely to effect to a significant degree –
(a) the safety or physical or mental integrity of the subjects of the trial; or
(b) the scientific value of the trial”.
Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
10 – 11 April 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 18 April 2024InformaUnited States
-
17 – 19 April 2024SCDM (Society of Clinical Data Management)Poland
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
即将进行的临床试验
-
Indiana University招聘中
-
Monopar Therapeutics尚未招聘胃癌 | 大肠癌 | 胰腺癌 | 卵巢癌 | 肺癌 | 膀胱癌 | 尿路上皮癌 | 三阴性乳腺癌 | 实体瘤,成人
-
Rigshospitalet, Denmark尚未招聘脑部疾病 | 先天性遗传病 | 新陈代谢,先天性错误 | 脑部疾病,代谢 | 苯丙酮尿症 | 脑部疾病,代谢性,先天性 | 氨基酸代谢,先天性错误 | 代谢性疾病丹麦